GLP-1 receptor agonists paradoxically provide cardioprotective benefits while simultaneously increasing sympathetic activity, heart rate, and blood pressure. The mechanisms reconciling these opposing cardiovascular effects remain unclear. Gap type: contradiction Source paper: Interactions between antidiabetes medications and heart-brain axis. (2025, Current opinion in endocrinology, diabetes, and obesity, PMID:39639832)
Landscape Summary: How do GLP-1 agonists achieve cardioprotection despite increasing sympathetic activity and cardiovascular stress? is a 0.79 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How do GLP-1 agonists achieve cardioprotection despite increasing sympathetic activity and cardiovascular stress? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: